Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: A 6-month, open-label, extension study

CNS Spectrums

Volumn 19, Issue 4, 2014, Pages 330-339

  Citrome, Leslie ^a   Weiden, Peter J ^b   McEvoy, Joseph P ^c   Correll, Christoph U ^d   Cucchiaro, Josephine ^e   Hsu, Jay ^e   Loebel, Antony ^e  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antipsychotic; effectiveness; lurasidone; schizophrenia; switch

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CHOLESTEROL; CREATINE KINASE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TIOTIXENE; TRIACYLGLYCEROL; ZIPRASIDONE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; INSULIN; LIPID; NEUROLEPTIC AGENT;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; BIPOLAR I DISORDER; CALGARY DEPRESSION SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; CONTUSION; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; DYSPHORIA; DYSTONIA; ELEVATED BLOOD PRESSURE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HEALTH SERVICES UTILIZATION QUESTIONNAIRE; HOMICIDAL IDEATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERSALIVATION; HYPERTENSION; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NECK PAIN; OPEN STUDY; OUTPATIENT CARE; PARANOIA; PARKINSONISM; PERSONAL EVALUATION OF TRANSITIONS IN TREATMENT SCORE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SHORT FORM 12; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TOOTH PAIN; TREATMENT DURATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; TRISMUS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA; ANXIETY DISORDER; CARDIOVASCULAR DISEASE; EXTRAPYRAMIDAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MEDICATION COMPLIANCE; METABOLIC DISORDER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE; AKATHISIA, DRUG-INDUCED; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; ANXIETY; DRUG SUBSTITUTION; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84906790526     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291300093X     Document Type: Article

References (35)

1. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010; 79(9): 1115-1124.
2. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009; 9: 54.
3. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002; 28(1): 17-29. (Pubitemid 34534747)
4. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007; 68(Suppl 4): 34-39. (Pubitemid 46762121)
5. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of ''switching'' medications. J Clin Psychiatry. 2007; 68(Suppl 6): 14-23. (Pubitemid 47026642)
6. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry. 1997; 58(Suppl 10): 63-72. (Pubitemid 27333183)
7. Weiden PJ. Switching in the era of atypical antipsychotics: an updated review. Postgrad Med. 2006; Spec No: 27-44.
8. Correll CU. Real life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006; 67(1): 160-161. (Pubitemid 43213296)
9. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008; 69(Suppl 1): 4-17.
10. Sunovion Pharmaceuticals Inc. Latuda: US package insert for Latuda (lurasidone HCl) tablets for oral use. July 2013. Available at: http://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed September 6, 2013.
11. United States Food and Drug Administration. FDA approves Latuda to treat schizophrenia in adults. Press release, October 28, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm. Accessed September 6, 2013.
12. Sunovion Pharmaceuticals Canada Inc. Sunovion Pharmaceuticals Canada Inc. announces Health Canada approval of once-daily LATUDATM (lurasidone HCl) for the treatment of patients with schizophrenia. Press release, June 15, 2012. Available at: http://www.sunovion.ca/news/pressReleases/20120615.pdf. Accessed September 6, 2013.
13. Sunovion Pharmaceuticals Canada Inc. Latuda: Product monograph for Latuda (lurasidone HCl) 40mg, 80 mg and 120mg film-coated tablets. July 24, 2013. Available at: http://www.sunovion.ca/monographs/latuda.pdf. Accessed September 6, 2013.
14. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011; 65(2): 189-210.
15. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012; 29(10): 815-825.
16. McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013; 74(2): 170-179.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 45(S212): 11-19.
18. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154(5): 672-676. (Pubitemid 19154942)
19. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988; 39(11): 1172-1177.
20. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 1994.
21. Guy W. EDCEU Assessment Manual for Psychopharmacology- Revised (DHEW Publ No ADM 76-338). Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:534-537.
22. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990; 3(4): 247-251. (Pubitemid 20228720)
23. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12): 1266-1277.
24. Browne G, Gafni A, Roberts J, Hoxby H. Approach to the measurement of costs (expenditures) when evaluating the efficiency of health and social programmes. Working Paper Series 92-12, System-Linked Research Unit. Hamilton, Ontario: McMaster University.
25. Voruganti L, Awad A. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002; 56(1-2): 37-46. (Pubitemid 34655466)
26. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3): 220-233. (Pubitemid 126433231)
27. Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010; 118(1-3): 271-278.
28. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013; 225(3): 519-530.
29. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebocontrolled trial. J Clin Psychiatry. 2009; 70(6): 829-836.
30. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013; 74(5): 507-515.
31. Silva R, Correll CU, Simonelli S, et al. Long-term safety and effectiveness of lurasidone in schizophrenia: results of a 22 month, open-label extension study. Poster NR6-37, 165th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 5-9, 2012.
32. Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1): 95-102.
33. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165-176.
34. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951-962.
35. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012; 26(9): 733-759.